Patients receiving treatment with this medication should be observed during and after therapy. HUS may occur at any point during therapy, with signs such as anemia, thrombocytopenia, and renal failure, especially when patients receive doses exceeding 60 mg. Fragmented red blood cells may also be present on peripheral smear.

The use of mitomycin in pregnant women remains unestablished; therefore, it is not recommended from a safety standpoint. Parenterally-administered mitomycin can cause fetal issues if given during pregnancy; it is classified into category D by the FDA. Breastfeeding is not recommended and is to be discontinued when receiving mitomycin therapy.